Daily Respiratory Research Analysis
Three impactful respiratory studies span clinical trials and mechanistic science. A multicenter NEJM RCT found no reduction in time to liberation from mechanical ventilation with PAV+ versus PSV, despite lower sedative exposure. A large ERJ RCT showed that microbiome-directed addition of a third antibiotic during CF exacerbations did not improve outcomes, while a mechanistic study identified Piezo1 activation (Yoda1) as a rapid bronchodilator strategy in mice.
Summary
Three impactful respiratory studies span clinical trials and mechanistic science. A multicenter NEJM RCT found no reduction in time to liberation from mechanical ventilation with PAV+ versus PSV, despite lower sedative exposure. A large ERJ RCT showed that microbiome-directed addition of a third antibiotic during CF exacerbations did not improve outcomes, while a mechanistic study identified Piezo1 activation (Yoda1) as a rapid bronchodilator strategy in mice.
Research Themes
- Ventilator weaning strategies in critical care
- Microbiome-informed antibiotic therapy in CF exacerbations
- Novel mechanosensitive ion channel targets for bronchodilation
Selected Articles
1. Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation.
In this multicenter RCT (n=573), PAV+ did not reduce time to successful liberation from mechanical ventilation compared with PSV (7.3 vs 6.8 days, P=0.58). Mortality, reintubation, tracheostomy, and ventilator-free days were similar, while PAV+ was associated with lower cumulative sedative exposure.
Impact: High-quality negative evidence directly informs ventilator weaning strategy and supports continued use of PSV as standard of care.
Clinical Implications: PSV should remain the default mode for weaning; PAV+ may be considered for sedation-sparing but is unlikely to shorten weaning time. Focus should remain on protocolized weaning and sedation optimization rather than switching modes.
Key Findings
- Median time to successful liberation: 7.3 days (PAV+) vs 6.8 days (PSV), P=0.58
- Day-90 mortality similar: 29.6% (PAV+) vs 26.6% (PSV)
- Lower sedative exposure with PAV+: −1.51±3.28 mg/kg midazolam-equivalent vs 0.04±0.97 mg/kg
- Serious adverse events comparable: 10.8% (PAV+) vs 9.8% (PSV)
Methodological Strengths
- International multicenter randomized design with adequate sample size
- Pre-registered trial with prespecified primary outcome and comprehensive safety reporting
Limitations
- Open-label nature inherent to ventilator mode interventions may introduce performance bias
- Sedation practices differed between groups, potentially confounding secondary outcomes
Future Directions: Evaluate targeted sedation-sparing strategies with PAV+ in subgroups (e.g., high sedation needs), and integrate protocolized weaning bundles with objective respiratory drive measures.
BACKGROUND: In critically ill patients, acceleration of liberation from mechanical ventilation is important in order to reduce the risk of complications and to improve long-term outcomes. Whether the use of proportional-assist ventilation with load-adjustable gain factors (PAV+) results in a shorter time to successful liberation from mechanical ventilation than pressure-support ventilation (PSV) is unclear. METHODS: In this international clinical trial, we randomly assigned adult patients who had been receiving mechanical ventilation for at least 24 hours and were able to undergo partial ventilatory support with PSV but were not yet ready for liberation from ventilation to undergo PAV+ (which targeted normal work of breathing) or PSV (which targeted a normal respiratory rate and tidal volume). The primary outcome was the time from randomization to successful liberation from mechanical ventilation. RESULTS: Across 23 centers in seven countries, 722 patients were enrolled, and 573 underwent randomization and were included in the analysis. The median time to successful liberation from mechanical ventilation was 7.3 days (95% confidence interval [CI], 6.2 to 9.7) in the PAV+ group and 6.8 days (95% CI, 5.4 to 8.8) in the PSV group (P = 0.58). The median number of ventilator-free days, the incidence of reintubation and tracheostomy, and the incidence of death by day 90 (29.6% in the PAV+ group and 26.6% in the PSV group), all of which were secondary outcomes, were similar in the two groups. With respect to sedative drugs, the mean (±SD) difference in the midazolam-equivalent dose at day 28 relative to the baseline dose was -1.51±3.28 mg per kilogram of body weight in the PAV+ group and 0.04±0.97 mg per kilogram in the PSV group. Serious adverse events occurred in 31 patients (10.8%) in the PAV+ group and in 28 patients (9.8%) in the PSV group (P = 0.79). CONCLUSIONS: The time to liberation from mechanical ventilation did not differ significantly between the group that underwent PAV+ and the group that underwent PSV. (Funded by the Canadian Institutes of Health Research and others; PROMIZING ClinicalTrials.gov number, NCT02447692.).
2. Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial.
In CFMATTERS, adding a third antibiotic guided by sputum microbiome sequencing during CF exacerbations did not improve clinical outcomes (e.g., ppFEV1) compared with usual care. Safety profiles were similar between groups.
Impact: Provides rigorous randomized evidence against routine microbiome-sequencing–guided escalation of antibiotics in CF exacerbations, informing stewardship and clinical pathways.
Clinical Implications: Routine addition of a third antibiotic based solely on sputum microbiome sequencing should not be adopted; standard culture-guided therapy remains appropriate. Emphasize antimicrobial stewardship and individualized care.
Key Findings
- 149 eligible exacerbations analyzed (usual care n=83; microbiome-directed n=66)
- No improvement in ppFEV1 with microbiome-directed addition versus usual therapy
- Overall clinical outcomes and safety did not differ between groups
Methodological Strengths
- Multicenter randomized controlled design across Europe and North America
- Integration of sputum microbiome sequencing within a pragmatic trial framework
Limitations
- Primary abstracted outcomes beyond ppFEV1 not fully detailed in summary
- Potential heterogeneity in exacerbation management across sites
Future Directions: Define patient subgroups who might benefit from microbiome-informed therapy, optimize sequencing turnaround and actionable thresholds, and integrate with pharmacokinetic/pharmacodynamic monitoring.
BACKGROUND: This study explores the effectiveness and safety of microbiome-directed antimicrobial therapy METHODS: A multicentre two-arm parallel randomised control trial conducted across Europe/North-America enrolled 223 participants (January 2015 to August 2017). All participants were chronically colonised with RESULTS: 149 participants had an eligible exacerbation (usual therapy n=83, microbiome-directed therapy n=66). There was no difference between the groups for ppFEV CONCLUSION: The addition of a third antibiotic based on sputum microbiome sequencing analysis did not result in improved clinical outcomes.
3. Piezo1 Agonist Yoda1 Induces Rapid Relaxation in Cultured Airway Smooth Muscle Cells and Bronchodilation in Mouse Models.
Yoda1, a Piezo1 agonist, rapidly decreased airway smooth muscle cell stiffness and traction force via calcium signaling and BK channel activation, and reduced airway resistance in methacholine-challenged mice in a dose-dependent fashion. Findings support Piezo1 as a therapeutic bronchodilator target.
Impact: Introduces a mechanosensitive ion channel as a druggable target for rapid bronchodilation, offering a potential new class of therapies for severe or refractory asthma.
Clinical Implications: While preclinical, the data justify further development of Piezo1 agonists and translational studies to assess safety, delivery, and efficacy in human asthma, especially where current bronchodilators are insufficient.
Key Findings
- Yoda1 rapidly decreased ASMC stiffness and traction force in vitro
- Mechanism involved calcium signaling and activation of large-conductance Ca2+-activated K+ (BK) channels
- Dose-dependent bronchodilation: reduced airway resistance in methacholine-challenged mice
Methodological Strengths
- Convergent in vitro biophysical measurements with in vivo functional readouts
- Dose–response assessment and mechanistic linkage to BK channel activation
Limitations
- Preclinical study without human subjects; safety and off-target effects of Piezo1 agonism unknown
- Specific ASMC/mouse strain details and long-term effects not delineated in abstract
Future Directions: Advance Piezo1 agonists with optimized pharmacology; explore inhaled delivery, selectivity, and safety; evaluate efficacy in diverse asthma phenotypes and human tissues.
Bronchodilators that relax airway smooth muscle cells (ASMCs) are essential for treating constrictive airway diseases such as asthma. However, the existing bronchodilators are often unable to control symptoms of severe asthmatic patients, leaving a pressing need to search for alternatives. Recent studies indicate that the transmembrane mechanosensitive channel, Piezo1, may provide a novel target for bronchodilation, as it mediates ASMC relaxation by means of calcium signaling and activation of large-conductance, calcium-activated potassium channels, and the Piezo1-specific agonist Yoda1 has been shown to reduce cell stiffness and traction force in cultured ASMCs after 24-hour incubation. Therefore, in this study, we further explored the potential of Yoda1 for inducing rapid ASMC relaxation and bronchodilation. We treated either cultured ASMCs or allergen-induced mouse models of asthma with Yoda1 at various doses and then assessed the resulting variations in cell stiffness, traction force, and molecular signaling of cultured ASMCs, as well as in airway resistance of the mouse models. We found that exposure to Yoda1 rapidly decreased cell stiffness; decreased traction force in association with induced calcium signaling and the activation of large-conductance, calcium-activated potassium channels in cultured ASMCs; and reduced airway resistance in methacholine-challenged mice in a dose-dependent manner. These results indicate that chemical activation of Piezo1 with specific agonist Yoda1 was, indeed, capable of inducing bronchodilation by relaxing ASMCs; thus, they provide insights into the development of Piezo1 agonist-based novel bronchodilators for treating constrictive airway disorders such as asthma.